{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:31:27Z","timestamp":1788838287740,"version":"build-2803163510"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Auranofin is an FDA-approved disease-modifying anti-rheumatic drug that has been used for decades for treatment of rheumatoid arthritis. This gold(I) compound has anti-inflammatory properties because it reduces IL-6 expression <jats:italic>via<\/jats:italic> inhibition of the NF-\u03baB-IL-6-STAT3 signaling pathway. Also, by inhibiting redox enzymes such as thioredoxin reductase, auranofin increases cellular oxidative stress and promotes apoptosis. Auranofin also possesses antiviral properties. Recently, it was reported that auranofin reduced by 95% SARS-CoV-2 RNA in infected human cells <jats:italic>in vitro<\/jats:italic> and decreased SARS-CoV-2-induced cytokine expression, including IL-6. During SARS-CoV-2 infection, a cytokine storm involving IL-6 increases severity of illness and worsens prognosis. Therefore, auranofin could, in our point of view, reduce pathology due to SARS-CoV-2-induced IL-6. COVID-19 is a rapidly-evolving respiratory disease now distributed worldwide. Strikingly high numbers of new COVID-19 cases are reported daily. We have begun a race to vaccinate people, but due to the complex logistics of this effort, the virus will continue to spread before all humans can be immunized, and new variants that may be less well contained by current vaccines are of concern. The COVID-19 pandemic has overwhelmed health care systems and new treatments to reduce mortality are urgently needed. We encourage to further evaluate the potential of auranofin in the treatment of COVID-19 <jats:italic>in vitro<\/jats:italic> and in animal models of SARS-CoV-2 infection and, if preliminary data are promising, in clinical trials with COVID-19 patients. In our opinion, auranofin has the potential to become a valuable addition to available therapies in this pandemic.<\/jats:p>","DOI":"10.3389\/fimmu.2021.683694","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T05:28:33Z","timestamp":1632288513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Will Auranofin Become a Golden New Treatment Against COVID-19?"],"prefix":"10.3389","volume":"12","author":[{"given":"Karine","family":"Sonzogni-Desautels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momar","family":"Ndao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"B1","unstructured":"Coronavirus Disease (COVID-19) Weekly Epidemiological Update2021"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-00031-0","article-title":"Could New COVID Variants Undermine Vaccines? Labs Scramble to Find Out","volume":"589","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"105778","DOI":"10.1016\/j.actatropica.2020.105778","article-title":"One Year Update on the COVID-19 Pandemic: Where are We Now","volume":"214","author":"Mishra","year":"2021","journal-title":"Acta Trop"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00480","article-title":"Treatment Options for COVID-19: A Review","volume":"7","author":"Ali","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 - Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30911-7","article-title":"The Place for Remdesivir in COVID-19 Treatment","volume":"21","author":"Young","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11739-020-02569-9","article-title":"COVID-19 Treatment Options: A Difficult Journey Between Failed Attempts and Experimental Drugs","volume":"16","author":"Bartoli","year":"2021","journal-title":"Intern Emerg Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 In Vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12941-020-00368-w","article-title":"Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2\/COVID-19","volume":"19","author":"Sharun","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"B10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41429-020-0336-z","article-title":"Ivermectin: A Systematic Review From Antiviral Effects to COVID-19 Complementary Regimen","volume":"73","author":"Heidary","year":"2020","journal-title":"J Antibiot (Tokyo)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1889","article-title":"The Approved Dose of Ivermectin Alone is Not the Ideal Dose for the Treatment of COVID-19","volume":"108","author":"Schmith","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.20-0271","article-title":"Ivermectin and COVID-19: Keeping Rigor in Times of Urgency","volume":"102","author":"Chaccour","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41392-020-0191-1","article-title":"Immune Response in COVID-19: Addressing a Pharmacological Challenge by Targeting Pathways Triggered by SARS-CoV-2","volume":"5","author":"Catanzaro","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa829","article-title":"High-Dose But Not Low-Dose Corticosteroids Potentially Delay Viral Shedding of Patients With COVID-19","volume":"72","author":"Li","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients With COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","unstructured":"Therapeutic Management of Adults With COVID-19"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.cell.2021.02.018","article-title":"Time-Resolved Systems Immunology Reveals a Late Juncture Linked to Fatal COVID-19","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000930","article-title":"The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin-6 Signaling in COVID-19-Related Systemic Inflammatory Response","volume":"8","author":"Arnaldez","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002322","article-title":"Involvement of Interleukin 6 in SARS-CoV-2 Infection: Siltuximab as a Therapeutic Option Against COVID-19","volume":"27","author":"Palanques-Pastor","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"B20","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s13063-020-04453-5","article-title":"Treatment of Severely Ill COVID-19 Patients With Anti-Interleukin Drugs (COV-AID): A Structured Summary of a Study Protocol for a Randomised Controlled Trial","volume":"21","author":"Maes","year":"2020","journal-title":"Trials"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1840549","article-title":"Overview on the Use of IL-6 Agents in the Treatment of Patients With Cytokine Release Syndrome (CRS) and Pneumonitis Related to COVID-19 Disease","volume":"29","author":"Zhou","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized With COVID-19 Pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients With Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in Patients Admitted to Hospital With COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"B26","unstructured":"COVID-19 Treatment Guidelines: Interleukin-6 Inhibitors"},{"key":"B27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: Repurposing an Old Drug for a Golden New Age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R D"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.5.560","article-title":"Auranofin","volume":"36","author":"Kean","year":"1997","journal-title":"Br J Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1983.tb03277.x","article-title":"Mechanism of Action, Pharmacology, Clinical Efficacy and Side Effects of Auranofin. An Orally Administered Organic Gold Compound for the Treatment of Rheumatoid Arthritis","volume":"3","author":"Furst","year":"1983","journal-title":"Pharmacotherapy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12272-008-1122-9","article-title":"Auranofin Inhibits Overproduction of Pro-Inflammatory Cytokines, Cyclooxygenase Expression and PGE2 Production in Macrophages","volume":"31","author":"Han","year":"2008","journal-title":"Arch Pharm Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.9.821","article-title":"Production of Interleukin-6 by Monocytes Isolated From Rheumatoid Arthritis Patients Receiving Second-Line Drug Therapy","volume":"33","author":"Crilly","year":"1994","journal-title":"Br J Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10787-012-0149-1","article-title":"The Biological Activity of Auranofin: Implications for Novel Treatment of Diseases","volume":"20","author":"Madeira","year":"2012","journal-title":"Inflammopharmacology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.virol.2020.05.002","article-title":"The FDA-Approved Gold Drug Auranofin Inhibits Novel Coronavirus (SARS-COV-2) Replication and Attenuates Inflammation in Human Cells","volume":"547","author":"Rothan","year":"2020","journal-title":"Virology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jcp.10377","article-title":"Overexpression of Thioredoxin Reductase 1 Regulates NF-Kappa B Activation","volume":"198","author":"Sakurai","year":"2004","journal-title":"J Cell Physiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01169","article-title":"Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention","volume":"11","author":"Hussman","year":"2020","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.09.097","article-title":"Auranofin, as an Anti-Rheumatic Gold Compound, Suppresses LPS-Induced Homodimerization of TLR4","volume":"350","author":"Youn","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25987","article-title":"In Silico Studies on the Comparative Characterization of the Interactions of SARS-CoV-2 Spike Glycoprotein With ACE-2 Receptor Homologs and Human TLRs","volume":"92","author":"Choudhury","year":"2020","journal-title":"J Med Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-010-0618-2","article-title":"TBK1-Targeted Suppression of TRIF-Dependent Signaling Pathway of Toll-Like Receptor 3 by Auranofin","volume":"33","author":"Park","year":"2010","journal-title":"Arch Pharm Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.11.5981","article-title":"Thiol-Reactive Metal Compounds Inhibit NF-Kappa B Activation by Blocking I Kappa B Kinase","volume":"164","author":"Jeon","year":"2000","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02679.x","article-title":"Auranofin Blocks Interleukin-6 Signalling by Inhibiting Phosphorylation of JAK1 and STAT3","volume":"122","author":"Kim","year":"2007","journal-title":"Immunology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling Serum Cytokines in COVID-19 Patients Reveals IL-6 and IL-10 are Disease Severity Predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B42","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The Role of Cytokines Including Interleukin-6 in COVID-19 Induced Pneumonia and Macrophage Activation Syndrome-Like Disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1136\/annrheumdis-2020-217523","article-title":"Antirheumatic Agents in COVID-19: Is IL-6 the Right Target","volume":"80","author":"Capecchi","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"102563","DOI":"10.1016\/j.autrev.2020.102563","article-title":"Why Judiciously Timed Anti-IL 6 Therapy may be of Benefit in Severe COVID-19 Infection","volume":"19","author":"Cunningham","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02947-4","article-title":"The Added Value of Pirfenidone to Fight Inflammation and Fibrotic State Induced by SARS-CoV-2 : Anti-Inflammatory and Anti-Fibrotic Therapy Could Solve the Lung Complications of the Infection","volume":"76","author":"Ferrara","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302470","article-title":"Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis","volume":"193","author":"Le","year":"2014","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"111023","DOI":"10.1016\/j.jinorgbio.2020.111023","article-title":"Anti-Fibrotic Activity of Gold and Platinum Complexes - Au(I) Compounds as a New Class of Anti-Fibrotic Agents","volume":"206","author":"Stratton","year":"2020","journal-title":"J Inorg Biochem"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2011.12.015","article-title":"Thioredoxin-1 and Protein Disulfide Isomerase Catalyze the Reduction of Similar Disulfides in HIV Gp120","volume":"44","author":"Reiser","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/chem.202004112","article-title":"Gold Metallodrugs to Target Coronavirus Proteins: Inhibitory Effects on the Spike-ACE2 Interaction and on PLpro Protease Activity by Auranofin and Gold Organometallics","volume":"26","author":"Gil-Moles","year":"2020","journal-title":"Chemistry"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41392-020-00215-6","article-title":"Door to the Cell for COVID-19 Opened, Leading Way to Therapies","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2020.11.016","article-title":"SARS-CoV2 Infectivity is Potentially Modulated by Host Redox Status","volume":"18","author":"Singh","year":"2020","journal-title":"Comput Struct Biotechnol J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1039\/D0DT02478C","article-title":"What is Holding Back the Development of Antiviral Metallodrugs? A Literature Overview and Implications for SARS-CoV-2 Therapeutics and Future Viral Outbreaks","volume":"49","author":"de Paiva","year":"2020","journal-title":"Dalton Trans"},{"key":"B54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17460441.2020.1819236","article-title":"Metallo Therapeutics for COVID-19. Exploiting Metal-Based Compounds for the Discovery of New Antiviral Drugs","volume":"16","author":"Cirri","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.04.014","article-title":"Host Oxidative Folding Pathways Offer Novel Anti-Chikungunya Virus Drug Targets With Broad Spectrum Potential","volume":"143","author":"Langsjoen","year":"2017","journal-title":"Antiviral Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328347bd77","article-title":"Gold Drug Auranofin Restricts the Viral Reservoir in the Monkey AIDS Model and Induces Containment of Viral Load Following ART Suspension","volume":"25","author":"Lewis","year":"2011","journal-title":"AIDS"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e944","DOI":"10.1038\/cddis.2013.473","article-title":"A Candidate Anti-HIV Reservoir Compound, Auranofin, Exerts a Selective 'Anti-Memory' Effect by Exploiting the Baseline Oxidative Status of Lymphocytes","volume":"4","author":"Chirullo","year":"2013","journal-title":"Cell Death Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704823","article-title":"Induction of Mitochondrial Permeability Transition by Auranofin, a Gold(I)-Phosphine Derivative","volume":"136","author":"Rigobello","year":"2002","journal-title":"Br J Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01947-16","article-title":"Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent","volume":"61","author":"Capparelli","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90483-7","article-title":"Auranofin Versus Injectable Gold. Comparison of Pharmacokinetic Properties","volume":"75","author":"Blocka","year":"1983","journal-title":"Am J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198611020-00003","article-title":"Clinical Pharmacokinetics of Oral and Injectable Gold Compounds","volume":"11","author":"Blocka","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.0c00190","article-title":"A Role for Metal-Based Drugs in Fighting COVID-19 Infection","volume":"11","author":"Marzo","year":"2020","journal-title":"Case auranofin ACS Med Chem Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.683694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T05:28:38Z","timestamp":1632288518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.683694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":62,"alternative-id":["10.3389\/fimmu.2021.683694"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.683694","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"article-number":"683694"}}